CareDx (CDNA) Aperçu de l'action
CareDx, Inc. fournit des solutions pour améliorer les résultats des patients transplantés et faire progresser la santé des organes aux États-Unis et dans le monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
CDNA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CareDx, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$26.18 |
| Plus haut sur 52 semaines | US$26.26 |
| Plus bas sur 52 semaines | US$10.96 |
| Bêta | 2.48 |
| Variation sur 1 mois | 21.04% |
| Variation sur 3 mois | 46.75% |
| Variation sur 1 an | 38.15% |
| Variation sur 3 ans | 211.67% |
| Variation sur 5 ans | -72.47% |
| Évolution depuis l'introduction en bourse | 161.80% |
Nouvelles et mises à jour récentes
Article d’analyse • Jun 21
CareDx (CDNA) Stock Could Be 1.5% Overvalued After AlloSure Study Buzz
CareDx (CDNA) is back in focus after fresh data from the Kidney Allograft Outcomes AlloSure Registry and a major nephrology journal publication highlighted the clinical use of its AlloSure test for transplant monitoring. See our latest analysis for CareDx. The recent AlloSure data release and upcoming American Transplant Congress presentations appear to have coincided with building momentum in CareDx, with an 11.5% 1 day share price return and a 21.04% 30 day share price return feeding into a...
Mise à jour du récit • Jun 15
CDNA: Oncology Expansion And Legal Resolution Will Shape Balanced 2026 Outlook
Analysts have raised their CareDx price target by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a modestly higher valuation. What's in the News CareDx reported Q1 revenue growth of 39% year over year, with Testing Services volume up 17%, and raised full year 2026 guidance to US$447 million to US$465 million in revenue and adjusted EBITDA of US$43 million to US$57 million, according to recent company updates.
Mise à jour du récit • Jun 01
CDNA: Higher 2026 Revenue Outlook And Legal Overhang Resolution Will Drive Repricing
Analysts have lifted their price target on CareDx by $1, based on updated assumptions for fair value, discount rate, revenue growth, profit margins, and a higher future P/E, as reflected in recent BTIG research. What's in the News CareDx reported that a qui tam action filed in February 2021 was dismissed by the United States District Court for the Eastern District of New York on April 23, 2026, with no monetary payment required, after the Department of Justice concluded its investigation in October 2024 without any finding of wrongdoing and declined further action.Recent updates
Article d’analyse • Jun 21
CareDx (CDNA) Stock Could Be 1.5% Overvalued After AlloSure Study Buzz
CareDx (CDNA) is back in focus after fresh data from the Kidney Allograft Outcomes AlloSure Registry and a major nephrology journal publication highlighted the clinical use of its AlloSure test for transplant monitoring. See our latest analysis for CareDx. The recent AlloSure data release and upcoming American Transplant Congress presentations appear to have coincided with building momentum in CareDx, with an 11.5% 1 day share price return and a 21.04% 30 day share price return feeding into a...Mise à jour du récit • Jun 15
CDNA: Oncology Expansion And Legal Resolution Will Shape Balanced 2026 Outlook
Analysts have raised their CareDx price target by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a modestly higher valuation. What's in the News CareDx reported Q1 revenue growth of 39% year over year, with Testing Services volume up 17%, and raised full year 2026 guidance to US$447 million to US$465 million in revenue and adjusted EBITDA of US$43 million to US$57 million, according to recent company updates.Mise à jour du récit • Jun 01
CDNA: Higher 2026 Revenue Outlook And Legal Overhang Resolution Will Drive Repricing
Analysts have lifted their price target on CareDx by $1, based on updated assumptions for fair value, discount rate, revenue growth, profit margins, and a higher future P/E, as reflected in recent BTIG research. What's in the News CareDx reported that a qui tam action filed in February 2021 was dismissed by the United States District Court for the Eastern District of New York on April 23, 2026, with no monetary payment required, after the Department of Justice concluded its investigation in October 2024 without any finding of wrongdoing and declined further action.Mise à jour du récit • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Seeking Alpha • Apr 18
CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results
Summary CareDx is a leading precision medicine company specializing in transplant diagnostics, recently divesting its lab products portfolio for $170 million to focus on core testing services. CDNA demonstrates solid revenue growth and improving gross margins, but faces stiff competition from Natera, limited differentiation, and ongoing regulatory headwinds. Despite positive cash flow and a low debt/equity ratio, risks include declining R&D spending, falling book value, insider selling, and policy uncertainty that could impact revenue. I maintain a Hold rating on CDNA, viewing shares as attractive below $18, but prefer Natera for growth-oriented investors given its stronger momentum and market position. Read the full article on Seeking AlphaMise à jour du récit • Apr 13
CDNA: Wider 2026 Guide And CMS Overhang Will Drive Repricing
Analysts have lifted their price target on CareDx by $1 to $26, citing a solid Q4, a 2026 revenue outlook set above Street estimates, and a view that shares look inexpensive even with ongoing CMS uncertainty. Analyst Commentary Street research points to a mixed but generally constructive view on CareDx, with analysts weighing a solid recent quarter and new long term revenue guidance against ongoing policy risks and execution questions.Mise à jour du récit • Mar 30
CDNA: Final MolDX LCD Decision Will Drive 2026 Outlook And Upside Potential
Narrative Update on CareDx Analysts have raised their implied fair value estimate for CareDx to $21.00 from $20.00. This reflects updated views on 2026 revenue guidance, reimbursement uncertainty and the stock's valuation relative to recent Street research commentary.Mise à jour du récit • Mar 16
CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing
The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth. Analyst Commentary Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.Mise à jour du récit • Mar 02
CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
The analyst price target for CareDx has been raised from $18 to $20. Analysts point to a higher assumed revenue growth outlook, a slightly higher future P/E, and management's 2026 revenue guidance, while still flagging uncertainty around the final CMS LCD and its impact on longer term growth and volumes.Mise à jour du récit • Feb 16
CDNA: MolDX LCD Outcome Will Temper Appeal Despite Solid 2025 Guidance
Analysts have lowered their outlook on CareDx, reducing the price target to $26. They see a less compelling risk reward profile given uncertainty around the final MolDX LCD and how it could affect 2026 revenue, longer term growth, and near term test volumes.
Mise à jour du récit • Feb 01
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Analysts have trimmed their fair value estimate for CareDx from US$28 to US$26, citing a less compelling risk reward outlook as revenue and longer term growth now appear more closely tied to uncertain reimbursement outcomes and a much higher assumed future P/E. Analyst Commentary Recent research points to a more cautious stance on CareDx, with the key concern being how much future revenue and growth now hinge on reimbursement decisions and a higher assumed future P/E multiple.Mise à jour du récit • Jan 18
CDNA: MolDX LCD Uncertainty Will Restrain Appeal Despite Raised Guidance
Narrative Update on CareDx The analyst price target for CareDx has been reset to US$18.00. This reflects what analysts see as a less compelling risk reward profile, given uncertainty around future revenue tied to the final MolDX LCD and the possibility that upcoming estimates and longer term growth expectations may be too optimistic.Mise à jour du récit • Jan 04
CDNA: Raised Guidance And Share Buyback Will Shape Balanced Outlook
Analysts have raised their price target on CareDx from 14 dollars to 18 dollars, citing expectations for stronger revenue growth and a higher future earnings multiple, despite a modestly higher discount rate and lower projected profit margins. What's in the News Shareholder derivative lawsuits against current and former directors are moving toward a proposed global settlement, with a final approval hearing scheduled for June 30, 2026 in the U.S. District Court for the Northern District of California (shareholder litigation notice).Mise à jour du récit • Dec 17
CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Analysts have nudged their price target on CareDx higher from around 21.83 dollars to 23.00 dollars, citing expectations for slightly faster revenue growth and a richer future valuation multiple, despite a more conservative view on long term profit margins and discount rates. What's in the News The board amended and restated company bylaws to adopt a majority voting standard for director elections, with plurality voting only in contested elections (company bylaws filing).Article d’analyse • Nov 29
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 25% gain in the last month alone...Article d’analyse • Nov 12
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
CareDx, Inc ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...Article d’analyse • Sep 19
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Those holding CareDx, Inc ( NASDAQ:CDNA ) shares would be relieved that the share price has rebounded 28% in the last...Article d’analyse • Aug 27
Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Key Insights The projected fair value for CareDx is US$10.87 based on 2 Stage Free Cash Flow to Equity Current share...Mise à jour du récit • Aug 15
Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
CareDx’s consensus price target was reduced from $27.50 to $22.20, primarily due to heightened reimbursement risk stemming from the proposed Palmetto MolDx LCD and recent share price volatility, despite operational stability and some analysts seeing undervaluation at current levels. Analyst Commentary Ongoing uncertainty surrounding the Palmetto MolDx draft Local Coverage Determination (LCD), which proposes to limit reimbursement for certain transplant tests.Article d’analyse • Jul 23
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
The CareDx, Inc ( NASDAQ:CDNA ) share price has fared very poorly over the last month, falling by a substantial 32...Article d’analyse • May 02
Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
Key Insights The projected fair value for CareDx is US$20.92 based on 2 Stage Free Cash Flow to Equity Current share...
Nouveau récit • Mar 24
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.Seeking Alpha • Mar 13
CareDx: Some Litigation Clouds Have Cleared
Summary CareDx, Inc. has cleared up some litigation and legal challenges since I last looked at this diagnostic concern last summer. The company continues to post solid revenue growth and has a rock-solid balance sheet. FY2024 saw progress on numerous fronts, and CDNA delivered margin increases and a massive increase in adjusted EBITDA. An updated analysis around CareDx, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Mar 11
Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
We didn't see CareDx, Inc's ( NASDAQ:CDNA ) stock surge when it reported robust earnings recently. We decided to have a...Seeking Alpha • Dec 30
CareDx: Too Risky For Me
Summary CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile. Management changes and negative employee reviews indicate potential internal instability, casting doubt on future company performance despite their innovative products. Despite strong gross margins and a solid balance sheet, CareDx's inability to turn a profit and questionable capital allocation methods make it a sell. Read the full article on Seeking AlphaArticle d’analyse • Nov 05
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
CareDx, Inc ( NASDAQ:CDNA ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Sep 29
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Summary CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives. Despite ongoing legal disputes with Natera, revised processes may protect future AlloSure revenues. CDNA's valuation is high, but its expanding revenues and recent insurance coverage wins justify a "Buy" rating for investors aware of inherent biotech risks. Read the full article on Seeking AlphaArticle d’analyse • Aug 01
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 34% in the last...Seeking Alpha • Jul 15
CareDx: Benefiting From Some Certainty
Summary Today, we circle back to diagnostic testing concern CareDx, Inc for the first time in 2024. The stock has moved up some 60% since the company delivered better than expected quarterly results in early May. The company has appointed a new CEO and seen some certainty around a key patent litigation lawsuit so far this year as well. Can the rally continue, or is the stock overdue for some profit taking? An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Apr 27
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
CareDx, Inc ( NASDAQ:CDNA ) shares have had a horrible month, losing 28% after a relatively good period beforehand. The...Article d’analyse • Mar 02
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
CareDx, Inc ( NASDAQ:CDNA ) shareholders would be excited to see that the share price has had a great month, posting a...Rendement pour les actionnaires
| CDNA | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 8.7% | 4.6% | -2.5% |
| 1Y | 38.2% | 36.5% | 20.1% |
Rendement vs Industrie: CDNA a dépassé le secteur US Biotechs qui a rapporté 34.1 % au cours de l'année écoulée.
Rendement vs marché: CDNA a dépassé le marché US qui a rapporté 21.2 % au cours de l'année écoulée.
Volatilité des prix
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: CDNA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CDNA ( 11% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1998 | 763 | John Hanna | caredx.com |
CareDx, Inc. propose des solutions pour améliorer les résultats des transplantations et faire progresser la santé des organes aux États-Unis et dans le monde. La société propose AlloSure Kidney, une solution d'ADN acellulaire dérivé du donneur (dd-cfDNA) pour les patients ayant subi une greffe de rein ; AlloMap Heart, une solution de profilage de l'expression génétique pour les patients ayant subi une greffe de cœur ; AlloSure Heart, une solution dd-cfDNA pour les patients ayant subi une greffe de cœur ; et AlloSure Lung, une solution dd-cfDNA pour les patients ayant subi une greffe de poumon. Elle propose également HeartCare, qui fournit des informations sur des processus biologiques distincts, tels que la quiescence immunitaire, la lésion active, le rejet cellulaire aigu et le rejet médié par les anticorps ; HistoMap Kidney, une solution qui identifie le rejet d'allogreffe et le type de rejet dans les tissus de biopsie de transplantation rénale ; et AlloHeme, un test de surveillance qui prédit la rechute chez les patients atteints de leucémie myéloïde aiguë et de syndromes myélodysplasiques.
CareDx, Inc. Résumé des fondamentaux
| CDNA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.35b |
| Bénéfices(TTM) | -US$8.19m |
| Recettes(TTM) | US$412.82m |
3.3x
Ratio P/S-165.1x
Ratio P/ELe site CDNA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CDNA compte de résultat (TTM) | |
|---|---|
| Recettes | US$412.82m |
| Coût des recettes | US$128.45m |
| Marge brute | US$284.37m |
| Autres dépenses | US$292.56m |
| Les revenus | -US$8.19m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.16 |
| Marge brute | 68.88% |
| Marge bénéficiaire nette | -1.98% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CDNA?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/22 01:05 |
| Cours de l'action en fin de journée | 2026/06/18 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CareDx, Inc. est couverte par 14 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |